An introduction to dendritic cell biology and analysis using syngeneic immuno-oncology models

Productive immunotherapy driven anti-tumor responses rely on the activation of T cells that target tumor-associated antigens (TAA). The dendritic cell (DC) plays an essential role in the activation of T cell antigen-specific responses, which occur naturally in the context of infection. However, this same process supports tumor-immune surveillance as well as active anti-tumor responses.

Why is cytotoxicity testing critical in medical device development?

Cytotoxicity testing is a critical step in medical device evaluation, but it comes with many challenges. Factors like device composition, sample preparation and contamination can impact biocompatibility results. With so much riding on accurate safety data, it is essential to understand the challenges and considerations for skillful navigation.

The Heart of the Matter: Early Risk Identification & Prevention are Key to Reducing Cardiovascular Disease

Heart disease costs employers and individuals nearly $1 billion a day in medical costs and lost productivity. According to some studies, approximately 800,000 Americans die each year from heart disease, stroke and other cardiovascular diseases. That accounts for one in every three deaths in the United States, and one of every six dollars employers spend on healthcare. And, it’s worse for women. Heart disease is the leading cause of death among women, and one of the most preventable.  How can employers help employees prepare for and avoid heart disease? Focusing on digital health, prevention and identifying risk early are key strategies to improving cardiovascular health outcomes. Watch this webinar to hear speakers share: The impact cardiovascular disease can have on workforce health Why women are most at risk  How early detection and prevention-focused care can fuel health programs and drive a healthier, more resilient and cost-effective workforce

Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort

Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer

Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics